In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
about
Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myelomaPomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma.Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma.Pomalidomide mitigates neuronal loss, neuroinflammation, and behavioral impairments induced by traumatic brain injury in rat.Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study.Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.Pomalidomide desensitization in a patient hypersensitive to immunomodulating agents.Safety and efficacy of pomalidomide, dexamethasone and pegylated liposomal doxorubicin for patients with relapsed or refractory multiple myeloma.The MIP-1α autocrine loop contributes to decreased sensitivity to anticancer drugs.Lenalidomide combined with low-dose cyclophosphamide and prednisone modulates Ikaros and Aiolos in lymphocytes, resulting in immunostimulatory effects in lenalidomide-refractory multiple myeloma patients
P2860
Q33432492-415D5980-52FC-415B-B2A6-B417640A0E4CQ33443411-33E407AF-437B-4176-AD34-C947B99F78DFQ35935794-1B596487-9738-4D7A-9740-043D32730473Q36115680-9D0301D7-277B-43FF-B4D7-13CF0C5D21CFQ36172671-031C7CE5-960D-42CB-8AA2-21BF96956710Q37045248-541FB58C-1707-4478-AF31-36E3019A6505Q37609489-569225B2-DDC1-411C-83FE-0CCE69EFC686Q38766508-842FCE6A-08EC-48E6-B657-E19B271EEACBQ41559549-B2FC74BD-C31A-4306-9B02-F1EC39FD0D90Q46147631-445BB7AA-66C7-4007-9E6C-6CB38DFCA4D5Q47618731-701F91F5-CFBD-4FE5-9896-C19CF7D494ABQ58552961-08F0A1B0-83F9-4FAD-AF11-A36F7C9FBA65
P2860
In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
In vivo murine model of acquir ...... ombination with dexamethasone.
@en
type
label
In vivo murine model of acquir ...... ombination with dexamethasone.
@en
prefLabel
In vivo murine model of acquir ...... ombination with dexamethasone.
@en
P2093
P2860
P50
P356
P1433
P1476
In vivo murine model of acquir ...... combination with dexamethasone
@en
P2093
A García-Gómez
A Pandiella
C C Bjorklund
L López-Corral
L San-Segundo
M V Mateos
P2860
P2888
P304
P356
10.1038/LEU.2014.238
P50
P577
2014-08-08T00:00:00Z
P6179
1047499887